PPARGC1A and amyotrophic lateral sclerosis: In conclusion, A‐1 treatment reduced motor neuron loss, improved gastrocnemius atrophy, and further delayed the progression of ALS disease via the AMPK/SIRT1/PGC‐1α pathway, which in turn increased mitochondrial biogenesis, and the AMPK/SIRT1/IL‐1β/NF‐κB pathway, which exerted neuroprotective effects via the reduction of neuroinflammation.